Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MPO | P05164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2718388 | 1.00 | POLB (0.32) | POLBMAPTRAB9AALDH1A1LMNA | |
| SCHEMBL2719916 | 0.86 | ERN1 (0.32) | MAPTALDH1A1MPO | |
| SCHEMBL15445445 | 0.82 | USP2 (0.36) | MAPTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL2717538 | 0.82 | USP2 (0.36) | MAPTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL2717541 | 0.82 | USP2 (0.36) | MAPTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL4090157 | 0.76 | ALDH1A1 (0.35) | POLBMAPTRAB9AALDH1A1LMNA | |
| SCHEMBL2717906 | 0.67 | MEN1 (0.34) | ALDH1A1LMNA | |
| SCHEMBL17539208 | 0.62 | HPGD (0.43) | POLBMAPTRAB9AALDH1A1LMNA | |
| SCHEMBL17503146 | 0.62 | HPGD (0.43) | POLBMAPTRAB9AALDH1A1LMNA | |
| SCHEMBL17503145 | 0.62 | HPGD (0.43) | POLBMAPTRAB9AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140031355-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2635565-A1 | 5 -CYANO-4, 6 -DIAMINOPYRIMIDINE OR 6 -AMINOPURINE DERIVATIVES AS PI3K- DELTA INHIBITORS | Amgen Inc. (US) | 2013-09-11 | — | — | EP | disclosed |
| WO-2012061696-A1 | 5 -CYANO-4, 6 -DIAMINOPYRIMIDINE OR 6 -AMINOPURINE DERIVATIVES AS PI3K- DELTA INHIBITORS | AMGEN INC. (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031355-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, SSB, MALT1 | POLB 3908/4885MAPT 2133/4885RAB9A 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.